Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited)
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited)
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 123, Issue S1, Pages 18-27
Publisher
Springer Science and Business Media LLC
Online
2020-12-08
DOI
10.1038/s41416-020-01071-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III Non-Small Cell Lung Cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)
- (2019) Solange Peters et al. ANNALS OF ONCOLOGY
- Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.
- (2019) Ferdinandos Skoulidis et al. JOURNAL OF CLINICAL ONCOLOGY
- Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
- (2019) Jhanelle E. Gray et al. Journal of Thoracic Oncology
- Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients
- (2018) Ashleigh C. McEvoy et al. BMC CANCER
- Mechanisms of resistance to immune checkpoint inhibitors
- (2018) Russell W Jenkins et al. BRITISH JOURNAL OF CANCER
- Challenges with biomarkers in cancer drug discovery and development
- (2018) Ecaterina Ileana Dumbrava et al. Expert Opinion on Drug Discovery
- Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.
- (2018) Gilberto Lopes et al. JOURNAL OF CLINICAL ONCOLOGY
- 30-day mortality following initiation of immunotherapy for advanced stage lung cancer
- (2018) J.S. Evans et al. LUNG CANCER
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179.
- (2018) Greg Andrew Durm et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of STK11/LKB1 mutations with primary resistance to PD-1/PD-L1 axis blockade in PD-L1 positive non-squamous NSCLC.
- (2018) Ferdinandos Skoulidis et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC).
- (2018) Luis G. Paz-Ares et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- (2018) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- Time to abandon single-site irradiation for inducing abscopal effects
- (2018) Eric D. Brooks et al. Nature Reviews Clinical Oncology
- Ceritinib versus chemotherapy in patients with ALK -rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
- (2017) Alice T Shaw et al. LANCET ONCOLOGY
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy for Unresectable Stage III Non–Small-Cell Lung Cancer
- (2017) Naiyer A. Rizvi et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC)
- (2016) S.J. Antonia et al. ANNALS OF ONCOLOGY
- PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2016) Suresh Senan et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer
- (2015) W. E. E. Eberhardt et al. ANNALS OF ONCOLOGY
- Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non–Small-Cell Lung Cancer: KCSG-LU05-04
- (2015) Jin Seok Ahn et al. JOURNAL OF CLINICAL ONCOLOGY
- Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
- (2015) Jeffrey D Bradley et al. LANCET ONCOLOGY
- Radiotherapy and Immunogenic Cell Death
- (2015) Encouse B. Golden et al. SEMINARS IN RADIATION ONCOLOGY
- Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody
- (2015) R. Stewart et al. Cancer Immunology Research
- STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
- (2014) Liufu Deng et al. IMMUNITY
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
- (2014) Liufu Deng et al. JOURNAL OF CLINICAL INVESTIGATION
- Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
- (2013) Charles Butts et al. LANCET ONCOLOGY
- Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410
- (2011) W. J. Curran et al. JNCI-Journal of the National Cancer Institute
- Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
- (2010) Anne Aupérin et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023
- (2008) Karen Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- (2008) Giorgio Vittorio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis
- (2007) Ping Zhang et al. MOLECULAR IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More